Lyell Immunopharma, Inc. Common Stock LYEL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T07:55:41.854Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:21:49.602456584Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-07T07:55:41.567831+00:00
Lyell Immunopharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 11.86 | 377.2% | 36.7% | |||
| 30Δ | 13.01 | 313.6% | 28.9% | |||
| 35Δ | 13.92 | 266.0% | 22.8% | |||
| 40Δ | 27.80 | 463.3% | 103.6% | |||
| 45Δ | 21.16 | 366.7% | 58.9% | |||
| 50Δ | 17.51 | 294.7% | 34.3% | |||
| 55Δ | 15.70 | 243.6% | 22.1% | 16.06 | 151.7% | 8.4% |
| 60Δ | 14.62 | 204.6% | 14.8% | 16.29 | 136.3% | 6.9% |
| 65Δ | 13.88 | 173.6% | 10.0% | 16.52 | 121.0% | 5.3% |
| 70Δ | 13.44 | 151.8% | 7.1% | 16.75 | 105.7% | 3.8% |
| 75Δ | 12.99 | 130.4% | 4.3% | 16.97 | 90.4% | 2.3% |
| 80Δ | 12.26 | 143.8% | 3.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.86
- IV
- 377.2%
- B/E move
- 36.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.01
- IV
- 313.6%
- B/E move
- 28.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.92
- IV
- 266.0%
- B/E move
- 22.8%
40Δ
- Pseudo strike
- 27.80
- IV
- 463.3%
- B/E move
- 103.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 21.16
- IV
- 366.7%
- B/E move
- 58.9%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 17.51
- IV
- 294.7%
- B/E move
- 34.3%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 15.70
- IV
- 243.6%
- B/E move
- 22.1%
- Pseudo strike
- 16.06
- IV
- 151.7%
- B/E move
- 8.4%
60Δ
- Pseudo strike
- 14.62
- IV
- 204.6%
- B/E move
- 14.8%
- Pseudo strike
- 16.29
- IV
- 136.3%
- B/E move
- 6.9%
65Δ
- Pseudo strike
- 13.88
- IV
- 173.6%
- B/E move
- 10.0%
- Pseudo strike
- 16.52
- IV
- 121.0%
- B/E move
- 5.3%
70Δ
- Pseudo strike
- 13.44
- IV
- 151.8%
- B/E move
- 7.1%
- Pseudo strike
- 16.75
- IV
- 105.7%
- B/E move
- 3.8%
75Δ
- Pseudo strike
- 12.99
- IV
- 130.4%
- B/E move
- 4.3%
- Pseudo strike
- 16.97
- IV
- 90.4%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 12.26
- IV
- 143.8%
- B/E move
- 3.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 158.43% | |
| 154.26% | |
| 167.77% | |
| 177.51% | |
| 183.33% | |
| 222.19% | |
| 211.85% | |
| 229.13% | |
| 110.84% | |
| 115.80% | |
| 116.21% | |
| 113.81% | |
| 112.81% | |
| 126.31% | |
| 131.25% | |
| 131.85% | |
| 130.42% | |
| 137.62% | |
| 139.30% | |
| 162.01% | |
| 160.79% | |
| 175.88% | |
| 205.89% | |
| 255.06% | |
| 153.99% | |
| 157.95% | |
| 157.61% | |
| 176.65% | |
| 183.85% | |
| 191.93% | |
| 204.72% | |
| 211.84% | |
| 210.50% | |
| 227.78% | |
| 295.88% | |
| 289.51% | |
| 176.75% |
Biotechnology
MANE
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New…
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and…
More →MCRB
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host…
More →MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of…
More →MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered…
More →